These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27809878)

  • 21. γ-Synuclein Expression Is a Malignant Index in Oral Squamous Cell Carcinoma.
    Cheng JC; Chiang MT; Lee CH; Liu SY; Chiu KC; Chou YT; Huang RY; Huang SM; Shieh YS
    J Dent Res; 2016 Apr; 95(4):439-45. PubMed ID: 26661712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
    Liutkauskiene S; Janciauskiene R; Jureniene K; Grizas S; Malonyte R; Juozaityte E
    BMC Cancer; 2015 Mar; 15():105. PubMed ID: 25879527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.
    Liu H; Liu W; Wu Y; Zhou Y; Xue R; Luo C; Wang L; Zhao W; Jiang JD; Liu J
    Cancer Res; 2005 Sep; 65(17):7635-43. PubMed ID: 16140929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients.
    Tastekin D; Kargin S; Karabulut M; Yaldız N; Tambas M; Gurdal N; Tatli AM; Arslan D; Gok AF; Aykan F
    Tumour Biol; 2014 Dec; 35(12):11871-7. PubMed ID: 25142230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway.
    Zhang J; Liu XH; Li C; Wu XX; Chen YL; Li WW; Li X; Gong F; Tang Q; Jiang D
    J Exp Clin Cancer Res; 2020 May; 39(1):79. PubMed ID: 32381034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
    Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
    Gershenson DM; Sun CC; Lu KH; Coleman RL; Sood AK; Malpica A; Deavers MT; Silva EG; Bodurka DC
    Obstet Gynecol; 2006 Aug; 108(2):361-8. PubMed ID: 16880307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.
    Morgan J; Hoekstra AV; Chapman-Davis E; Hardt JL; Kim JJ; Buttin BM
    Gynecol Oncol; 2009 Aug; 114(2):293-8. PubMed ID: 19476987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stage-specific expression of breast cancer-specific gene gamma-synuclein.
    Wu K; Weng Z; Tao Q; Lin G; Wu X; Qian H; Zhang Y; Ding X; Jiang Y; Shi YE
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):920-5. PubMed ID: 14504205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting synuclein-gamma to counteract drug resistance in cancer.
    Singh VK; Jia Z
    Expert Opin Ther Targets; 2008 Jan; 12(1):59-68. PubMed ID: 18076370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.